Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?
作者信息
Wilson Carole L, Hung Chi F
机构信息
1 Division of Pulmonary, Critical Care, Allergy and Sleep Medicine Medical University of South Carolina Charleston, South Carolina and.
2 Division of Pulmonary, Critical Care, and Sleep Medicine University of Washington Seattle, Washington.
出版信息
Am J Respir Cell Mol Biol. 2019 Apr;60(4):386-387. doi: 10.1165/rcmb.2018-0387ED.
Abstract
摘要
相似文献
1
Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?对抗特发性肺纤维化的又一武器？
Am J Respir Cell Mol Biol. 2019 Apr;60(4):386-387. doi: 10.1165/rcmb.2018-0387ED.
2
The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.酪氨酸激酶抑制剂 TAS-115 可减轻小鼠博来霉素诱导的肺纤维化。
Am J Respir Cell Mol Biol. 2019 Apr;60(4):478-487. doi: 10.1165/rcmb.2018-0098OC.
3
Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis.超微化棕榈酰乙醇胺（PEA-um(®)）治疗特发性肺纤维化
Pharmacol Res. 2016 Sep;111:405-412. doi: 10.1016/j.phrs.2016.07.010. Epub 2016 Jul 8.
4
Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.B 细胞中增强的 Bruton 酪氨酸激酶和特发性肺纤维化患者的自身反应性 IgA。
Respir Res. 2019 Oct 24;20(1):232. doi: 10.1186/s12931-019-1195-7.
5
Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice.150kDa 氧调节蛋白（ORP150）的表达可刺激博来霉素诱导的小鼠肺纤维化和功能障碍。
Biochem Biophys Res Commun. 2012 Sep 7;425(4):818-24. doi: 10.1016/j.bbrc.2012.07.158. Epub 2012 Aug 7.
6
Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway.安罗替尼通过 TGF-β1 信号通路减轻博来霉素诱导的肺纤维化。
J Pharm Pharmacol. 2020 Jan;72(1):44-55. doi: 10.1111/jphp.13183. Epub 2019 Oct 28.
7
Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis.Prominin-1/CD133+肺上皮祖细胞可预防博来霉素诱导的肺纤维化。
Am J Respir Crit Care Med. 2009 May 15;179(10):939-49. doi: 10.1164/rccm.200809-1390OC. Epub 2009 Feb 20.
8
The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis.博来霉素诱导的动物肺损伤的发病机制及其在人类特发性肺纤维化中的适用性。
Exp Lung Res. 2015 Mar;41(2):57-73. doi: 10.3109/01902148.2014.979516. Epub 2014 Dec 16.
9
Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.他莫昔芬通过靶向 TGFβ-PI3K-Akt 通路改善肺纤维化。
PLoS One. 2017 Oct 18;12(10):e0186615. doi: 10.1371/journal.pone.0186615. eCollection 2017.
10
Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis.ATG4B蛋白酶和自噬在博来霉素诱导的肺纤维化中的重要作用。
Autophagy. 2015 Apr 3;11(4):670-84. doi: 10.1080/15548627.2015.1034409.
引用本文的文献
1
Identification and analysis of diverse programmed cell death patterns in idiopathic pulmonary fibrosis using microarray-based transcriptome profiling and single-nucleus RNA sequencing.使用基于微阵列的转录组分析和单核RNA测序鉴定和分析特发性肺纤维化中多种程序性细胞死亡模式
Front Med (Lausanne). 2025 Jun 18;12:1534903. doi: 10.3389/fmed.2025.1534903. eCollection 2025.
2
Identification and validation of autophagy-related gene expression for predicting prognosis in patients with idiopathic pulmonary fibrosis.鉴定和验证自噬相关基因表达，以预测特发性肺纤维化患者的预后。
Front Immunol. 2022 Sep 20;13:997138. doi: 10.3389/fimmu.2022.997138. eCollection 2022.
3
Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.靶向精氨琥珀酸合成酶 1（ASS1）缺陷性肺纤维化的治疗。
Mol Ther. 2021 Apr 7;29(4):1487-1500. doi: 10.1016/j.ymthe.2021.01.028. Epub 2021 Jan 26.
4
Update in Interstitial Lung Disease 2019.2019年间质性肺疾病的进展
Am J Respir Crit Care Med. 2020 Aug 15;202(4):500-507. doi: 10.1164/rccm.202002-0360UP.
本文引用的文献
1
The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.酪氨酸激酶抑制剂 TAS-115 可减轻小鼠博来霉素诱导的肺纤维化。
Am J Respir Cell Mol Biol. 2019 Apr;60(4):478-487. doi: 10.1165/rcmb.2018-0098OC.
2
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.TAS-115通过抑制c-MET和PDGFRα信号通路治疗滑膜肉瘤的潜力
BMC Cancer. 2017 May 16;17(1):334. doi: 10.1186/s12885-017-3324-3.
3
A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.尼达尼布和吡非尼酮的一种新型抗纤维化机制。抑制胶原纤维组装。
Am J Respir Cell Mol Biol. 2017 Jul;57(1):77-90. doi: 10.1165/rcmb.2016-0217OC.
4
Therapeutic and pathological roles of fibroblast growth factors in pulmonary diseases.成纤维细胞生长因子在肺部疾病中的治疗和病理作用。
Dev Dyn. 2017 Apr;246(4):235-244. doi: 10.1002/dvdy.24468. Epub 2016 Dec 29.
5
The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.靶向MET/血管内皮生长因子受体（VEGFR）的酪氨酸激酶抑制剂也可减弱前列腺癌诱导的FMS依赖的破骨细胞分化和骨破坏。
J Biol Chem. 2016 Sep 30;291(40):20891-20899. doi: 10.1074/jbc.M116.727875. Epub 2016 Aug 18.
6
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.特发性肺纤维化的药物治疗：系统评价与网状Meta分析
Chest. 2016 Mar;149(3):756-66. doi: 10.1016/j.chest.2015.11.013. Epub 2016 Jan 13.
7
Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.尼达尼布对特发性肺纤维化患者来源的肺成纤维细胞的抗纤维化作用。
Respir Res. 2014 Dec 12;15(1):157. doi: 10.1186/s12931-014-0157-3.
8
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的 3 期临床试验。
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
9
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
10
The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.新型 VEGFR/MET 靶向激酶抑制剂 TAS-115 具有显著的体内抗肿瘤活性和良好的耐受性特征。
Mol Cancer Ther. 2013 Dec;12(12):2685-96. doi: 10.1158/1535-7163.MCT-13-0459. Epub 2013 Oct 18.
Zotero 插件